

# **CAR T-Cell Therapy for Multiple Myeloma: What's Involved, Potential Outcomes**

May 2nd, 2024

**Presenter:** Tulio Rodríguez MD, City of Hope

This presentation lasts 38 minutes, followed by 15 minutes of Q&A.

**Summary:** CAR T-cell therapy is a new treatment for patients with multiple myeloma. This presentation explains what CAR T cell therapy is, how effective it is for myeloma patients, and potential side effects.

## **Key Points:**

- CAR T Cell therapy is a novel treatment that has changed the way advanced myeloma is treated.
- Studies have shown that patients treated with CAR T-cell therapy experience improved overall response rates, progression-free survival, and overall survival.
- There are potential complications of CAR cell therapy like cytokine release syndrome, neurotoxicity, and cytopenia, but these side effects are treatable, and, in most people, they resolve.

## **Highlights:**

(02:20) There is currently no known cure for multiple myeloma. However, with appropriate therapy, survival can be prolonged with a good quality of life.

(02:41) Multiple myeloma is characterized by recurrences and periods of remission. It can become refractory (does not respond to treatment).

(06:18) There have been many advances in the treatment of multiple myeloma. The drugs to treat it can be grouped into three families:

immunomodulators (lenalidomide, pomalidomide); proteasome inhibitors (bortezomib, velcade), and monoclonal antibodies.

(09:23) CAR T cell therapy is a treatment that involves T-cells that are genetically modified to recognize and destroy cancer cells.

(17:42) Potential complications of CAR T-cell therapy are treatable, and, in most people, they resolve.

(23:11) In a study of 275 patients, the CAR T-cell therapy Abecma® helped 81% of patients with multiple myeloma.

(25:10) In another study, a different CAR T-cell product, Carvykti®, helped up to 97% of patients.